Zuzana Tothova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/798519/publications.pdf Version: 2024-02-01



Ζυζανία Τοτμουλ

#	Article	IF	CITATIONS
1	Genetic analysis of cancer drivers reveals cohesin and CTCF as suppressors of PD-L1. Proceedings of the United States of America, 2022, 119, .	3.3	12
2	Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML. JCI Insight, 2021, 6, .	2.3	39
3	Cohesin mutations in myeloid malignancies. Blood, 2021, 138, 649-661.	0.6	22
4	Inner nuclear protein Matrin-3 coordinates cell differentiation by stabilizing chromatin architecture. Nature Communications, 2021, 12, 6241.	5.8	25
5	Intergenerational epigenetic inheritance of cancer susceptibility in mammals. ELife, 2019, 8, .	2.8	43
6	Doubling Down on Mutant RAS Can MEK or Break Leukemia. Cell, 2017, 168, 749-750.	13.5	3
7	Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. Cell Stem Cell, 2017, 21, 547-555.e8.	5.2	71
8	Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML. Cell, 2016, 165, 303-316.	13.5	200
9	Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. Cancer Discovery, 2016, 6, 368-381.	7.7	215
10	Hemophagocytic Syndrome and Critical Illness. Journal of Intensive Care Medicine, 2015, 30, 401-412.	1.3	80
11	Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation. Nature Biotechnology, 2014, 32, 1262-1267.	9.4	1,351
12	New Strategies in Myelodysplastic Syndromes: Application of Molecular Diagnostics to Clinical Practice. Clinical Cancer Research, 2013, 19, 1637-1643.	3.2	16
13	A Radical Bailout Strategy for Cancer Stem Cells. Cell Stem Cell, 2009, 4, 196-197.	5.2	16
14	p16INK4a Is a Key Downstream Mediator of the Deleterious Effects of FoxO Deficiency on Maintenance of the Hematopoietic Stem Cell Compartment Blood, 2008, 112, 1405-1405.	0.6	0
15	FoxOs Are Critical Mediators of Hematopoietic Stem Cell Resistance toÂPhysiologic Oxidative Stress. Cell, 2007, 128, 325-339.	13.5	1,416